Search clinical trials for: MRG003

Total 60 results

Shanghai Miracogen Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

China
Shanghai Miracogen Inc.

Completed

A Study of MRG003 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors

Advanced Solid Tumors

China
Shanghai Miracogen Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.

Advanced or Metastatic Gastric Cancer | Advanced or Metastatic Gastroesophageal Junction Carcinoma

China
Shanghai Miracogen Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Advanced or Metastatic Biliary Tract Cancer

China
Shanghai Miracogen Inc.

Recruiting

Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.

Locally Advanced Gastric Cancer | Metastatic HER2 Positive Gastroesophageal Junction Cancer

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors

Advanced Solid Tumor

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Advanced or Metastatic Biliary Tract Cancer

China
Huashan Hospital

Not yet recruiting

Evaluation of the Safety, Tolerability and Efficacy of Gene Therapy Drug for Late Onset Pompe Disease (LOPD)

Pompe Disease (Late-onset)

China
Shanghai Miracogen Inc.

Not yet recruiting

A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

Non-small- Cell Lung Cancer (NSCLC)

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Metastatic Urothelial Carcinoma | Locally Advanced Urothelial Cancer

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Advanced or Metastatic Breast Cancer

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Advanced Solid Tumors | Advanced or Metastatic Gastric Cancer | Advanced or Metastatic Gastroesophageal Junction Cancer

United States
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

Breast Cancer With Liver Metastases

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.

Advanced Malignant Solid Tumors

China
MedDay Pharmaceuticals SA
Eurofins Optimed

Terminated

RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects

Healthy Volunteers | Impaired Renal Function

France, Hungary
Prothena Biosciences Limited

Completed

Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis

Psoriasis

United States
Prothena Biosciences Limited

Completed

Single Ascending Dose Study of PRX003 in Healthy Subjects

Psoriasis

United States
MedDay Pharmaceuticals SA
Eurofins Optimed

Terminated

HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subjects

Healthy Volunteers | Hepatic Impairment of Moderate Child Pugh Category

France, Hungary
Quoin Pharmaceuticals

Recruiting

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

Netherton Syndrome

United States
MedDay Pharmaceuticals SA

Unknown

Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis (MS-ON)

Multiple Sclerosis

United Kingdom, France
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Compare the Pharmacokinetics of BR9003A and BR9003 in Healthy Adult Subjects

Smoking Cessation

Korea, Republic of
MedDay Pharmaceuticals SA

Unknown

Effect of MD1003 in Spinal Progressive Multiple Sclerosis (MS-SPI)

Multiple Sclerosis

France
Boryung Pharmaceutical Co., Ltd

Completed

A Multi Doses Study to Compare the Pharmacokinetics of BR9003A and BR9003 in Healthy Adult Subjects

Smoking Cessation

Korea, Republic of
Shanghai Refreshgene Technology Co., Ltd.

Recruiting

Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular Degeneration

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

United States, China
MedDay Pharmaceuticals SA
Quotient Sciences

Completed

Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-MD1003 in Healthy Male Subjects

Healthy Volunteers

United Kingdom
i-SEP

Completed

Clinical Investigation Evaluating a New Autotransfusion Device in Cardiac Surgery (i-TRANSEP)

Hemorrhage | Blood Loss | Surgical Blood Loss

France
Shanghai Miracogen Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Recurrent or Metastatic Nasopharyngeal Carcinoma

China
RinuaGene Biotechnology Co., Ltd.

Not yet recruiting

A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3

Cervical Intraepithelial Neoplasia Grade 2/3 | Human Papillomavirus Associated Intraepithelial Neoplasia | Human Papillomavirus Type 16 Infection | Human Papillomavirus Type 18 Infection
Metagone Biotech Inc.

Completed

Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment With Solid Tumor

Solid Tumor

Taiwan
Lemonex

Recruiting

Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203)

COVID-19 Infection | COVID-19 Vaccine Adverse Reaction

Korea, Republic of
Anagram Therapeutics, Inc.

Recruiting

Phase 1 Study to Assess Safety and Efficacy of ANG003

Exocrine Pancreatic Insufficiency

United States
Quoin Pharmaceuticals

Recruiting

Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome

Netherton Syndrome

United States
Mylan Pharma UK Ltd.

Completed

An Open Study to Assess the Robustness of the CRC749 Inhaler

Asthma | COPD

United Kingdom
MedDay Pharmaceuticals SA

Completed

SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study

Charcot-Marie-Tooth Disease | Peripheral Neuropathy | Chronic Inflammatory Demyelinating Polyneuropathy | Charcot-Marie-Tooth Disease Type 1A | Charcot-Marie-Tooth Disease, Type 1B | Anti-MAG Neuropathy

France
MedDay Pharmaceuticals SA

Terminated

Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) (SPI2)

Multiple Sclerosis

United States, Spain, Canada, Australia, United Kingdom, Belgium, Turkey, Czechia, Poland, Italy, Hungary, Germany, Sweden
MedDay Pharmaceuticals SA

Completed

MD1003-AMN MD1003 in Adrenomyeloneuropathy

Adrenoleukodystrophy | Adrenomyeloneuropathy | AMN

France, Germany, Spain
MedDay Pharmaceuticals SA

Completed

Effect of MD1003 in Amyotrophic Lateral Sclerosis (MD1003-ALS)

Motor Neuron Disease | Amyotrophic Lateral Sclerosis | ALS

France
Nanfang Hospital, Southern Medical University

Not yet recruiting

First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors

Advanced Solid Tumors

China
Shire

Terminated

An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Placement of an Arteriovenous Graft to Facilitate Hemodialysis Access

Arteriovenous Graft

United States
Shanghai Miracogen Inc.

Not yet recruiting

A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN

Squamous Cell Carcinoma of the Head and Neck

China
Zhejiang Teruisi Pharmaceutical Inc.

Not yet recruiting

A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC (CRC)

Metastatic Colorectal Cancer (CRC)
MedDay Pharmaceuticals SA
Parexel; ERT: Clinical Trial Technology Solutions

Unknown

TQT2 Study to Evaluate the Effect of MD1003 on Cardiac Repolarization in Healthy Adult Subjects (TQT2)

Healthy Volunteers

United Kingdom
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Advanced Breast Cancer | Metastatic Breast Cancer

China
Shire

Completed

An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access

Arteriovenous Fistula

United States
Zhejiang Teruisi Pharmaceutical Inc.

Completed

A Study to Compare Pharmacokinetic and Safety of TRS003 to China-approved Bevacizumab and US-licensed Avastin®

Healthy

United States
Sanofi
Procter and Gamble

Completed

Risedronate in the Prevention of Osteoporosis in Postmenopausal Women

Osteoporosis, Postmenopausal

United States

Search clinical trials for: MRG003

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations